(China Alzheimer's Disease Neuroimaging Initiative)
PI： Kun Cheng Li， Jun Wang， HZ Wang
Alzheimer's disease (AD) is the most popular clinical neurodegenerative disease . The number of AD patients is about 36 millions in the world, mainly in the Asia-Pacific area. There are about 9 millions of AD patients in China, with ≈300 thousands of patients increased every year. The total cost of treatment is nearly 1.1 million RMB per AD patient and the average cost of carer for the AD patient is about 70 thousands RMB in one family in China. As the number of aging people is increasing, the increased AD patients will be a large burden to the family and society in China. Up to date, there is no efficient way to prevent and cure the disease. The challenge scenario is that once the patient obtained diagnosis of AD, the idea time of treatment has been deprived. As early intervention will not only improve the symptom but also postpone the progress of the disease, it is the key point to find the predictors of AD at early stage and biomarkers of progress monitors to patients and the population at risk for AD. Based on these concerns, Chinese researchers and clinicians on AD field initiated China-ADNI. China-ADNI will use US-ADNI uniform standard procedures to acquire longitudinal, multi-site biomarker (biofluid and neuroimaging) data on subjects with AD, MCI and age matched controls. All the protocols will be conducted as much compatible as to those of US-ADNI.
This project will provide useful data and methods to improve the design of future clinic trials and prevention for Alzheimer's disease.
The aims of this project are
(1) To organize a multisite longitudinal AD study through collaboration nationwide with compatibility of standard operating procedures of US-ADNI,
(2) To develop improved methods and validated biomarkers for AD early diagnosis and to define the indicators for detecting rate of progress of mild cognitive impairment (MCI) converting to AD in the dynamic evolution,
(3) To explore the relationship among multiple-modality MRI/PET, clinical cognitive and biofluid data for validation of biomarkers in the abnormality and the cognitive decline of patients,
(4) To construct the database that record longitudinal changes for spectrum of AD.
1. Expected number of subjects: 800 - 1000
① Healthy control: 200 - 250
② MCI: 400 - 500 (eMCI 200-250, late MCI 200-250)
③ Mild AD: 200 - 250
2. Duration of study: May, 2012. ~ April, 2017.
Preparation stage (Jan, 2010. ~ April, 2012.)
① Recruitment of subjects (May, 2012. ~ April, 2014; 24 months)
② Follow up duration for subjects (36 months)
③ Evaluation of subjects: every 6 months starting from baseline examination.
3. Subjects will have clinical /cognitive assessments, biofluid, 3T MRI and FDG /AV45 PET scans.
4. Dr. KunCheng Li, is the PI of China-ADNI, Co-PI: HongZheng Wang & Jun Wang; Cores of PIs: Clinic: Xiao-Ting Guan and JiHui Lv; MRI: ZhiGang Qi; PET: Fang Li; Biomarker: Yan Zhang and Ying Zhang; Statistics: Li Wang.
The applications have been submitted to governments. The first fund has been issued from government and more funds will be issued later.
Some pharmas have sponsored several times of China-ADNI symposiums and are looking for deeper co-orperation in the future.
China-ADNI started to recruit subjects clinically. More information will be released.